Caroline Wyatt: The fight to reverse damage caused by MS – BBC News
By Dr. Matthew Watson
Image caption Caroline Wyatt visited Prof Robin Franklin to find out more about a drug that might help stop the progression of MS
"I don't like to think of the future. It's such a big question mark. I just keep living in the present."
Karine Mather was diagnosed with MS when she was 27, although she noticed the first symptoms much earlier.
It started off as a mental-health issue with anxiety and depression, she remembers. Later, she noticed she was starting to limp when she walked longer distances.
Karine began using a walker to help with her balance and stamina, and then a scooter when she could no longer walk very far.
"I got to the stage where the wheelchair became quite liberating, and gave me back a sense of freedom again. Now I rely on the power-chair full-time because I can't stand by myself any more."
Now Karine and her wife, Sarah, have had to give up their full-time jobs.
Karine was forced to stop working as a customer service adviser at a bank because she could no longer fulfil the physical demands of work and Sarah gave up working as a data analyst so she could take care of Karine.
Now 34, Karine retains the use of just one hand, and suffers pain, stiffness and spasticity in her body that has got worse as the disease has progressed.
"It feels like a fist clenching all the time. And I have days when my mind is cloudy and I miss out words and sentences."
Both remain upbeat but the financial, as well as the emotional, impact of MS has been huge.
Karine's MS is the type known as "primary progressive", or PPMS, which meant that for the first years after diagnosis, no disease-modifying treatment was available.
One new drug - Ocrevus, or ocrelizumab - was recently licensed for early PPMS in the UK but came too late to help Karine.
Now the MS Society is launching an ambitious "Stop MS" appeal, aiming to raise 100m to fund research over the next decade into treatments that can stop the progression of disability in MS.
Since being diagnosed with MS in 2015, after many years of symptoms, I've been looking for anything that might help slow or even stop the progression of my MS, which affects the nerves in my brain and spinal cord.
I last wrote about my MS after travelling to Mexico for an autologous stem cell transplant (aHSCT) in 2017.
Sadly, despite initial improvements, I'm now back to where I was before: slowly but surely getting worse.
The only improvements that have endured are the lifting of some of the crushing brain fog I had before HSCT and less hesitation in my speech.
For both, I am eternally grateful, as they mean I can continue to work at the BBC, in the job I love.
However, I have no idea how long this reprieve will last.
The fatigue that had long been my worst symptom is now back with a vengeance, so that staying awake throughout a busy working day remains a challenge.
That MS fatigue did lift for a few months, and it felt miraculous. I awoke every day refreshed. But then it returned, and I awake after eight full hours fast asleep feeling as if I haven't been to bed at all.
The ageing process - including menopause - has almost certainly been a factor in the worsening of some symptoms.
Ageing cells repair less well, and with my faulty immune system apparently determined to keep stripping away the myelin sheath that should protect my nerves, I'm less able now to repair the damage than I was when the disease first began to affect me in around 1992.
Since 2016, I've had to walk using a stick to aid my balance. It is sparkly-topped; an effort to make the accoutrements of disability just a little more cheery.
Dizziness is now a constant companion. It rarely goes away, making car travel or even buses a nightmare. Just turning my head too fast can make me stagger or fall over.
And for the past year or two, my right foot has begun to drag along the ground thanks to foot drop, meaning that I trip more often because I can't fully raise it.
I am always grateful to the strangers who kindly stop to help me up from the uneven pavement when I do fall.
Perhaps most worrying for me is that my right hand no longer works as it used to, catching on the computer keyboard as my outer fingers drag lazily along the keys, sullenly refusing my brain's command to lift.
In the mornings, both my hands and my feet are numb and frozen, then painfully full of pins and needles before warming up enough to be usable a few hours later.
When I wake, I wonder how long it might be until these hands and feet barely function at all, and quickly push that unwelcome thought away.
I'm well aware how very lucky I am that the progression of my MS has been relatively slow - at least until recently. I've learned how better to conserve energy for the things that really matter, though I still chafe at how little I manage to achieve.
Having enough energy to cook a meal from scratch on a day off is a cause for rejoicing. I'm still learning how to save up enough energy for family and friends, and not use up all of my much-depleted ration for work or research.
I have had to face the fact that I have now probably gone from the relapsing-remitting phase of MS (for which a dozen or so treatments exist) into the secondary progressive phase, for which there is currently no treatment licensed in the UK to stop the relentless progression that will affect so many of the 100,000 or more of us living with MS here.
But that may be about to change.
Anna Williams, professor of regenerative neurology at the University of Edinburgh, is looking at how the brain responds to MS damage and how the fatty myelin sheath under attack in MS can be restored more efficiently.
"We have to look at ways to stop the nerves dying," she says. "We want to be able to try to limit that either by keeping the nerves alive, or keeping them working better."
Repurposing existing drugs to help with remyelination should prove the quickest route to therapies for progressive forms of MS, because creating and licensing new ones is a much lengthier and more expensive process.
Prof Williams still sees patients at the Anne Rowling Clinic of Regenerative Neurology in Edinburgh, named in memory of the Harry Potter author J K Rowling's mother, who had MS. (The author this year donated 15m for research at the unit.)
"At the moment, with PPMS or SPMS, we can always give relief for pain or stiffness but we won't change the course of the disease.
"So for those patients, to slow or stop or reverse the disease can only be done with more research, and money is critical for research."
The biggest trial yet in the UK for patients with secondary progressive MS is the MS STAT2 trial, conducted by Prof Jeremy Chataway for the UCL Queen Square Institute of Neurology in London.
The trial is still recruiting at 30 centres across the UK to look at whether simvastatin, a drug used to treat high cholesterol, can slow or stop disability progression. If so, it has the potential to become one of the first disease-modifying therapies for people with secondary progressive MS.
And perhaps most encouraging of all, Prof Robin Franklin and his team at the Wellcome-MRC Cambridge Stem Cell Institute recently published research suggesting a common diabetes drug - metformin - could hold the key to stopping disease progression in MS.
Costing just a few pence per tablet, metformin appears to have an ability to restore cells to a younger, healthier state and encourage myelin regrowth.
The next question is whether it works in people as well as it does in the lab.
Prof Franklin says: "This is a drug that's well tolerated and widely available. There is every reason to believe that the effects that we have seen - which have been so spectacular - will translate into humans.
"This is the great frontier of MS therapy. We're good at stopping the inflammation in MS. What we're not so good at doing is repairing the damage. All this work has given us some real hope that this medicine will reverse the damage done by MS."
I certainly feel rather more hopeful than I did.
I've changed as much about my lifestyle as I can - prioritising sleep, eating healthily, largely giving up alcohol, doing yoga and stretching every day, and cutting back on stress, be that reporting from war zones or attending too many BBC meetings.
But I'm all too aware that time is against me as my ageing brain and body struggle to repair the damage done in their lengthy continuing battle with my own immune system.
My hope now is that these trials will show good enough results in the next few years for at least one or two of the drugs to be rapidly approved for MS so they can help people like Karine and me before it's too late.
I ask Karine what she makes of the current research.
She is suitably succinct.
"I'm sitting here with just the one limb working and I'm thinking - quicker, please."
Visit link:
Caroline Wyatt: The fight to reverse damage caused by MS - BBC News
- Much-anticipated human trial aiming to repair spinal cord damage about to begin - ABC News - October 21st, 2024
- The Science Of Health: Are Spinal Cord Injuries Irreversible? Know Science Advances That Can Cure Them In The Future - ABP Live - October 16th, 2023
- Evaluating the Growth Prospects of the Global Nerve Repair & Regeneration Market at a CAGR of 6.5% | Emergen - EIN News - April 21st, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 17th, 2023
- Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx for the Treatment of ALS - Marketscreener.com - February 21st, 2023
- My Back Is All F*cked Up 55-Year-Old Joe Rogan Curses at Worst Jiu-Jitsu for Painful Health Condition - EssentiallySports - February 21st, 2023
- Brain and Spinal Cord Tumors: Hope Through Research - January 3rd, 2023
- 14.3 The Brain and Spinal Cord Anatomy & Physiology - January 3rd, 2023
- Stem Cell Therapy for Spinal Cord Injury - PubMed - January 3rd, 2023
- Spinal cord injury - Diagnosis and treatment - Mayo Clinic - December 25th, 2022
- Spinal Cord Injury: Hope Through Research | National Institute of ... - December 1st, 2022
- Stem cell controversy - Wikipedia - October 13th, 2022
- Stem Cells Australia | Australian research, stem cell treatments and ... - October 13th, 2022
- The eye and stem cells: the path to treating blindness - October 13th, 2022
- World's first stem cell treatment for spina bifida delivered during fetal surgery - UC Davis Health - October 13th, 2022
- Fighting One Disease or Condition per Day - Daily Kos - October 13th, 2022
- UPDATE: NurExone Signs Letter of Intent with Nanometrix for Its Exosome and Cargo Molecular Profiling AI-Driven Technology - Yahoo Finance - October 13th, 2022
- Global Cell Therapy Market Report (2022 to 2028) - Featuring Thermo Fisher Scientific, MaxCyte, Danaher and Avantor Among Others -... - October 13th, 2022
- Horizon Therapeutics plc Announces New UPLIZNA (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS... - October 13th, 2022
- Physiology, Spinal Cord - StatPearls - NCBI Bookshelf - October 5th, 2022
- IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 ... - October 5th, 2022
- Revolutionary Jab that Could Repair Spinal Cord Injuries Developed by Scientists - Good News Network - October 5th, 2022
- How the 'Love Hormone' Oxytocin May Help Heal Heart Muscles - Healthline - October 5th, 2022
- Unlocking the Mysteries of Brain Regeneration Groundbreaking Study Offers New Insight - SciTechDaily - October 5th, 2022
- In Conversation: How to understand chronic pain - Medical News Today - October 5th, 2022
- New drug could cure aggressive brain cancer stopping tumours in their tracks... - The US Sun - September 27th, 2022
- Rehabilitating spinal cord injury and stroke with graphene and gaming - Nanowerk - September 19th, 2022
- Induced Pluripotent Stem Cells Market Reaches at a CAGR of 8.0% in the Forecast Periods [2021-2031] - BioSpace - September 19th, 2022
- Axolotls can regenerate their brains - Big Think - September 19th, 2022
- IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the... - September 11th, 2022
- Spinal Muscular Atrophy: Causes and importance of early diagnosis for proactive management - Firstpost - September 11th, 2022
- Increasing Road Accidents and Fall Injuries among Aged Population Primarily Driving Need for Orthopedic Navigation Systems: Fact.MR Analysis - Yahoo... - September 3rd, 2022
- Culture of human nasal olfactory stem cells and their extracellular vesicles as advanced therapy medicinal products - Newswise - August 10th, 2022
- Curious kids: what is inside teeth? - The Conversation - August 10th, 2022
- Human placental mesenchymal stem cells derived exosomes improved functional recovery via attenuating apoptosis and increasing axonal regeneration... - August 2nd, 2022
- How the Regenerative Properties of Glioblastoma Can Be Terminated - Gilmore Health News - August 2nd, 2022
- New TSXV listing looks to address the $3B spinal cord injury treatment market (NRX.V) - FXStreet - July 25th, 2022
- Human iPSC co-culture model to investigate the interaction between microglia and motor neurons | Scientific Reports - Nature.com - July 25th, 2022
- Negligence in treatment of diseases like glioblastoma can be fatal, seminar told - The News International - July 25th, 2022
- What lab-grown cerebral organoids are revealing about the brain - New Scientist - July 25th, 2022
- Innovative Therapies, Care Equity Highlight 2022 ASCO Annual Meeting - Targeted Oncology - July 16th, 2022
- Global Stem Cell Manufacturing Market Value Projected To Reach USD 21.71 Billion By 2029, Registering A CAGR Of 9.1% - Digital Journal - July 16th, 2022
- Stem Cell Therapy Market Is Expected To Reach USD 455.61 Billion By 2027 At A CAGR Of 16 percent By Forecast 2027 Says Maximize Market Research (MMR)... - June 30th, 2022
- This startup wants you to have a personal stem cell stash - Freethink - June 30th, 2022
- Parents of 12-Year-Old Boy Praying for a Miracle, Appealing UK Judge's Decision to Remove Life Support - CBN.com - June 30th, 2022
- The end of Roe v. Wade affects more than just abortion - Vox.com - June 30th, 2022
- Horizon Therapeutics plc Submits Regulatory Filing for UPLIZNA (inebilizumab) in Brazil - Business Wire - June 20th, 2022
- Effect of Electrical Stimulation on Spinal Cord Injury: In Vitro and In Vivo Analysis - Newswise - June 11th, 2022
- First-of-its-Kind Stem Cell and Gene Therapy Highlighted at Annual Stem Cell Meeting - Newswise - June 11th, 2022
- UK Judge to Decide if 12-Year-Old Will Be Removed from Life Support, Parents Beg for More Time to Heal - CBN.com - June 11th, 2022
- 'This is my life, and I'll try anything to save it': Woman with MS raising funds for treatment - The Brandon Sun - May 29th, 2022
- Racing Thoughts: Quadriplegic Man Drives Race Car With His Brain - Newsy - May 29th, 2022
- Physical therapy for vertigo: Exercises, benefits, and more - Medical News Today - May 29th, 2022
- Researchers find new function performed by almost half of brain cells - Medical News Today - May 13th, 2022
- Texas Family Fights to Access $2.1 Million Treatment for Baby - NBC 5 Dallas-Fort Worth - May 13th, 2022
- Severe COVID-19 may cause cognitive deficits equivalent to 20 years of aging - Medical News Today - May 13th, 2022
- Stem Cell Magic: 5 Promising Treatments For Major Medical Conditions - Study Finds - April 29th, 2022
- Neural Stem Cell Therapy For Spinal Cord Injury To Tap Into The Potential Of Stem Cells - Optic Flux - April 15th, 2022
- Still Blooming: Sams mission to raise money for spinal cord injury research - 7NEWS - April 15th, 2022
- Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung... - April 15th, 2022
- Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss - Galveston County Daily News - March 22nd, 2022
- COVID-19: Even mild to moderate infection may cause brain anomalies - Medical News Today - March 22nd, 2022
- Scots mum with MS says 50k treatment abroad is 'last hope' of halting disease - Daily Record - January 18th, 2022
- Mending the gap: U of T's Molly Shoichet joins team developing new treatments for spinal cord injuries - News@UofT - January 18th, 2022
- Spinal Cord Injury Information Page | National Institute ... - January 3rd, 2022
- Dancing molecules successfully repair severe spinal cord ... - January 3rd, 2022
- Best 2021 Medical Breakthroughs And Treatments to Beat Cancer, Alzheimer's, Diabetes & More - Good News Network - January 3rd, 2022
- Global Regenerative Medicine Market is Expected to Reach USD 57.08 Billion by 2027, Growing at a CAGR of 11.27% Over the Forecast Period. -... - December 23rd, 2021
- Scientists unravel a gene function that helps the genesis of neurons - Research Matters - December 23rd, 2021
- The 10 Most Compelling Research Stories of 2021 PharmaLive - PharmaLive - December 23rd, 2021
- 2021: The year in review | YaleNews - Yale News - December 23rd, 2021
- Polymyositis Pipeline to Progress with New and Emerging Drugs for Treatment, Analyzes DelveInsight - GlobeNewswire - December 10th, 2021
- Cell and Gene Therapy Market to reach US$ 47,095.2 Mn by end of 2028, Says Coherent Market Insights - PRNewswire - November 22nd, 2021
- From asthma to cancer to infertility, the new treatments, jabs and meds making us healthier... - The Sun - November 22nd, 2021
- Improving motor neuron-like cell differentiation of hEnSCs by the combination of epothilone B loaded PCL microspheres in optimized 3D collagen... - November 8th, 2021
- Akiko Nishiyama Explains the Many Strengths of a Degree in Physiology and Neurobiology - UConn Today - UConn Today - October 28th, 2021
- Team finds way to enhance stem cell therapy for CNS injuries - BioPharma-Reporter.com - October 28th, 2021
- 'Rogue' antibodies found in brains of teens with delusions and paranoia after COVID-19 - Livescience.com - October 28th, 2021
- Traumatic Spinal Cord Injury: An Overview of ... - October 16th, 2021
- Role of Stem Cells in Treatment of Neurological Disorder - October 16th, 2021